American Academy of Dermatology

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
American Academy, Ulcerative colitis, BDCA2, American Association of Immunologists, CDAI, American Academy of Dermatology, PD-1, IND, Week, AAI, Therapy, Patient, Graft-versus-host disease, Rheumatoid arthritis, AAD, Atopic dermatitis, BTLA, SAN, UC, Pharmaceutical industry

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

AMERICAN ACADEMY OF DERMATOLOGY SURVEY SHOWS OUTDOOR WORKERS MORE AT RISK FOR SKIN CANCER THAN AVERAGE AMERICANS

Retrieved on: 
tisdag, maj 7, 2024
Moles, UPF, American Academy, University, Cancer, Perspiration, Blister, Carcinoma, Risk, Skin, Burn, American Academy of Dermatology, Hand, MD, Dermatology, Sunburn, Skin cancer, Life, Tanning, AAD, Melanoma, SPF, Human, Swimming, Emergency medical services, UV, Clothing, Cosmetics

ROSEMONT, Ill., May 7, 2024 /PRNewswire/ -- A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that outdoor workers – like those who work in construction, landscaping, emergency medical services, and postal delivery – are far more likely to get sunburned and tanned, putting themselves at increased risk for skin cancer, compared to the average American. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone – and especially those who work outdoors – to practice safe sun to protect themselves from the sun's harmful rays and reduce their risk of developing skin cancer.

Key Points: 
  • According to the survey, half of outdoor workers were sunburned in 2023, compared to 36 percent reported by the general American population.
  • One in 10 outdoor workers had sunburns severe enough to cause blisters, a rate double that of the general population.
  • And nearly 80 percent of outdoor workers got a tan or darker skin as a result of sun exposure, compared to 67 percent of Americans overall.
  • Tanning and unprotected sun exposure are major risk factors for skin cancer, the most common form of cancer in the United States and one of the most preventable types of cancer.

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
måndag, april 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

Wingderm® Shines Bright in the U.S.A., Continuously Expanding the Local Business Network

Retrieved on: 
tisdag, april 16, 2024
Nutrient, American Academy, American Academy of Dermatology, Annual general meeting, Absorption, Communication, Conference, Society, Professional, AAD

Both events provided invaluable opportunities for Wingderm® to showcase its cutting-edge technologies and establish a stronger presence in the United States of America.

Key Points: 
  • Both events provided invaluable opportunities for Wingderm® to showcase its cutting-edge technologies and establish a stronger presence in the United States of America.
  • Wingderm® representatives presented and showcased devices on-site, offering in-depth consultations to visitors and facilitating opportunities for communication and collaboration with practitioners.
  • We remain dedicated to advancing the field of medical aesthetics through innovative technologies that empower practitioners and enhance patient outcomes."
  • We hope to show our professionalism to each partner we collaborate with in the near future!

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
måndag, mars 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
måndag, mars 11, 2024
American Academy of Dermatology, Microbiota, Marketing, FDA, U.S. FDA, Skin, Forehead, Entrepreneurship, Risk, AAD, Safety, GI, Red, Rosacea, Minocycline, Patient, Clinical trial, Erythema, Vagina, Microbiology, American Academy

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting 

Retrieved on: 
måndag, mars 4, 2024
SAN, AAD, MHS, American Academy of Dermatology, Dermatology, MD, American Academy

SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
  • Dr. Gilly Munavalli, MD, MHS, FACMS will present Sofwave’s new Pure Impact™ Strength and Muscle Toning module to fellow dermatologists and meeting participants for the first time in the United States.
  • Sofwave Event Detail at AAD:

Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
fredag, mars 8, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Skin, Week, Psoriasis, American Academy of Dermatology, FDA, Atopic dermatitis, Validation, Treatment, AAD, JD, White, Alaska Natives, American Indians, American Academy, Pharmaceutical industry

“Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.

Key Points: 
  • “Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.
  • Secondary endpoints in the pivotal studies included the proportion of patients who achieved ≥75% improvement in the Eczema Area and Severity Index (EASI75).
  • Baseline Demographics Across ADORING Pivotal Phase 3 Trials:
    Approximately 50% of patients who enrolled had skin of color.
  • New Data on VTAMA cream from ADORING 1 and ADORING 2 for the Treatment of AD in Patients with Skin of Color Presented at AAD 2024 – Primary and Secondary Endpoints:

LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

Retrieved on: 
onsdag, mars 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Adolescence, EVP, American Academy of Dermatology, Ichthyosis, Atopic dermatitis, Pain, Dermatology, Calendar, Annual general meeting, AAD, Safety, Pharmacokinetics, Abstract, CHE, Congress, LEO, ASCEND, Leo Pharma, American Academy, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.
  • The event is being held from March 8th to 12th in San Diego, California.
  • “Our growing body of clinical evidence reinforces our passion and commitment to advancing the standard of care in medical dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer.
  • I am proud that we can follow up on our 2023 AAD program with this level of critical data,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
måndag, mars 4, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cream, American Academy of Dermatology, Safety, Randomness, Atopic dermatitis, Ageing, Autoimmunity, Treatment, Dermatology, Inflammation, AAD, Vitiligo, Prurigo, Hidradenitis suppurativa, Abstract, American Academy, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.